Učitavanje...
Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis
BACKGROUND: Patients may experience improved quality of life (QoL) without complete clearance of skin disease. The Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score correlates with the Symptoms and Emotions subscales of Skindex-29, a measure of QoL, down to CDASI-A s...
Spremljeno u:
| Izdano u: | Br J Dermatol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6917999/ https://ncbi.nlm.nih.gov/pubmed/31206600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18223 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|